Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because
they have dramatic efficacy. At the same time, safety concerns about biologics have been …

Advances in the treatment of malignant and inflammatory diseases have developed over
time, with increasing use of chemotherapeutic and immunosuppressive agents of a range of …

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for
psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but …

Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Hepatitis B virus reactivation (HBVr) can occur in patients treated with immunosuppressive
medications. Risk stratification for HBVr based on hepatitis B virus (HBV) serology and viral …

The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …